Alzheimer’s

Lilly's Donanemab gets CDSCO approval for early Alzheimer's treatment

Eli Lilly has secured CDSCO marketing authorisation for donanemab, an amyloid-targeting therapy for adults with early symptomatic Alzheimer's

Scientists find special cells in brain that can stop Alzheimer's: Study

In a study published in Nature, the team found that microglia with lower levels of a transcription factor called PU.1 and higher expression of a receptor known as CD28 help reduce brain inflammation

Can Ozempic slow Alzheimer's? Inside Novo Nordisk's big brain bet

Novo Nordisk's blockbuster weight-loss drug Ozempic is now being tested in Alzheimer's patients in global trials that may redefine how metabolism links to brain health

Body fat may secretly fuel Alzheimer's disease, finds new research

New research from Houston Methodist reveals how obesity may directly drive Alzheimer's disease.Scientists discovered that tiny messengers released by fat tissue, called extracellular vesicles, can carry harmful signals that accelerate the buildup of amyloid-b plaques in the brain.These vesicles even cross the blood-brain barrier, making them powerful but dangerous connectors between body fat and brain health.The study, "Decoding Adipose-Brain Crosstalk: Distinct Lipid Cargo in Human Adipose-Derived Extracellular Vesicles Modulates Amyloid Aggregation in Alzheimer's Disease," was published on October 2 in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.It explores the link between obesity, which affects about 40% of the U.S population, and the dreaded neurodegenerative disease affecting more than 7 million people in the U.S.The research was led by Stephen Wong, Ph.D., the John S. Dunn Presidential Distinguished Chair in Biomedical Engineering .Alongside Wong, ..

This Indian discovery may replace brain surgery for neuro disorders

From boosting dopamine to reducing toxic proteins, a new Indian nanomaterial may help treat neurodegenerative diseases without surgery or invasive devices

Rapid health reforms, new treatments required to tackle Alzheimer's: Study

A rapid reform to healthcare systems, public policy and attitude in society would be required to address burden of Alzheimer's disease in population, even as medications and blood tests present a potential in diagnosis and treatment, researchers say in a Lancet Series. Alzheimer's disease -- the most common form of dementia -- is an ageing-related neurological disorder which steadily impacts one's memory and thought processes, eventually interfering with daily activities. Describing new treatments and diagnostic methods for the condition in a series of three papers in The Lancet journal, the international team of researchers said that medications -- lecanemab and donanemab -- could slow down Alzheimer's disease from advancing. The drugs, which target specific proteins in a cell, have shown an efficacy comparable to that of drugs for cancer and autoimmune disorders such as rheumatoid arthritis and multiple sclerosis, the team said. They added that however, high costs of medicines, .

This simple test can help spot silent inflammation linked to heart disease

From heart disease to cancer and Alzheimer's, this simple test detects hidden inflammation that can warn of serious health problems before symptoms start

Study finds four symptom pathways that may lead to Alzheimer's disease

A study has identified four distinct clusters of symptoms, including psychiatric and cardiovascular, that can progressively lead to Alzheimer's disease -- an ageing-related condition in which memory and speech steadily declines, eventually disrupting daily activities. Researchers from the University of California, Los Angeles, US, said the study offers new insights into how the disorder can develop over time rather than from isolated risk factors. "We found that multi-step trajectories can indicate greater risk factors for Alzheimer's disease than single conditions," first author Mingzhou Fu, a medical informatics pre-doctoral student at the University of California, said. "Understanding these pathways could fundamentally change how we approach early detection and prevention," Fu said. The study, published in the journal eBioMedicine Part of THE LANCET Discovery Science, analysed records from the 'University of California Health Data Warehouse'. From data of more than 5,700 patien

Study finds four symptom pathways that may lead to Alzheimer's disease

A study has identified four distinct clusters of symptoms, including psychiatric and cardiovascular, that can progressively lead to Alzheimer's disease -- an ageing-related condition in which memory and speech steadily declines, eventually disrupting daily activities. Researchers from the University of California, Los Angeles, US, said the study offers new insights into how the disorder can develop over time rather than from isolated risk factors. "We found that multi-step trajectories can indicate greater risk factors for Alzheimer's disease than single conditions," first author Mingzhou Fu, a medical informatics pre-doctoral student at the University of California, said. "Understanding these pathways could fundamentally change how we approach early detection and prevention," Fu said. The study, published in the journal eBioMedicine Part of THE LANCET Discovery Science, analysed records from the 'University of California Health Data Warehouse'. From data of more than 5,700 patien

Feeling low in midlife may be linked to dementia risk, new studies find

New studies reveal a strong link between depression and mood disorders in mid to late life and the risk of developing dementia later on. Experts say early detection could be key

First blood test for Alzheimer's in US from June, starting at 50 hospitals

The test was cleared for use in people at least 55 years old and who exhibit signs of the disease. It is designed to detect amyloid, a protein that can build up in the brain

Gene Hackman died of heart disease after wife succumbed to hantavirus

Actor Gene Hackman died of heart disease a full week after his wife died from hantavirus in their New Mexico hillside home, likely unaware that she was dead because he was in the advanced stages of Alzheimer's disease, authorities revealed Friday. Both deaths were ruled to be from natural causes, chief medical examiner Dr Heather Jarrell said alongside state fire and health officials at a news conference. Mr Hackman showed evidence of advanced Alzheimer's disease, Jarrell said. He was in a very poor state of health. He had significant heart disease, and I think ultimately that's what resulted in his death. Authorities didn't suspect foul play after the bodies of Hackman, 95, and Betsy Arakawa, 65, were discovered February 26. Immediate tests for carbon monoxide poisoning were negative. Investigators found that the last known communication and activity from Arakawa was February 11 when she visited a pharmacy, pet store and grocery before returning to their gated neighbourhood that .

Loneliness increases risk of dementia by over 30%, studies review suggests

Loneliness is a major risk factor that increases the risk of dementia by over 30 per cent, regardless of age or gender, a review of 21 long-term studies involving over six lakh participants worldwide has found. Loneliness, which involves one feeling dissatisfied with their social relationships, was also linked with symptoms preceding the stage of being diagnosed with dementia, such as cognitive impairment or decline. Both conditions affect decision-making, memory and thought process. However, dementia's symptoms are severe enough to interfere with one's daily functioning. The psychological state of feeling disconnected from society is now widely regarded as a risk factor for ill-health, even though studies have shown that loneliness cannot directly cause the disease. "Dementia is spectrum, with neuropathological changes that start decades before clinical onset. It is important to continue studying the link of loneliness with different cognitive outcomes or symptoms across this ...

USFDA approves second Alzheimer's drug that can modestly slow disease

U.S. officials have approved another Alzheimer's drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. The Food and Drug Administration approved Eli Lilly's Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer's. It's only the second drug that's been convincingly shown to delay cognitive decline in patients, following last year's approval of a similar drug from Japanese drugmaker Eisai. The delay seen with both drugs amounts to a matter of months about seven months, in the case of Lilly's drug. Patients and their families will have to weigh that benefit against the downsides, including regular IV infusions and potentially dangerous side effects like brain swelling. Physicians who treat Alzheimer's say the approval is an important step after decades of failed experimental treatments. I'm thrilled to have different options to help my patients, said Dr. Suzanne Schindler, a .

Climate change could lead to spread, worsening of mental conditions: Study

"In order to work properly, the brain has to be maintained within a relatively narrow temperature range," said Sanjay Sisodiya, a professor at the UCL Queen Square Institute of Neurology

Espresso coffee may prevent Alzheimer's symptoms, lab study finds

Compounds in espresso coffee may inhibit a process that is believed to be involved in the onset of Alzheimer's disease, according to early findings of a study conducted in lab. To make espresso coffee, hot water is forced through finely ground coffee beans, creating a concentrated extract. This is often used as a base for other drinks, including the trendy espresso martini. Recent research has suggested that coffee could also have beneficial effects against certain neurodegenerative diseases, including Alzheimer's disease. In healthy people, tau proteins help stabilise structures in the brain, but when certain diseases develop, the proteins can clump together into fibrils -- a process that is believed to be involved in the onset of Alzheimer's. The study, published in the Journal of Agricultural and Food Chemistry, nalaysed if compounds in espresso could prevent tau aggregation in vitro. Researchers from the University of Verona in Italy pulled espresso shots from store-bought bea

Eli Lilly's drug donanemab seen as a turning point in dementia fight

Drug slows Alzheimer's by 60% for mildly impaired patients in trial

Found a cocktail of drugs that reverses ageing, claim Harvard researchers

The team discovered six chemical cocktails which reversed the ageing process in both human and mice skin cells 'by several years'

Eisai Alzheimer's drug gets full US approval, widening access to therapy

The broader clearance from the Food and Drug Administration marks a milestone for treatment of the dementia that afflicts some 6 million Americans

Intermittent fasting helps protect the brain from diseases like Alzheimer's

Alzheimer's disease is an increasingly urgent global issue. The World Health Organization predicts that the number of people with the condition will triple by 2050